Business
Lexicon Announces Proposed Public Offering of Common Stock
THE WOODLANDS, Texas, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced that it has commenced an underwritten public offering to offer and sell, subject to market and other conditions, shares of its common stock, par value $0.001. In addition, Lexicon intends to grant the underwriters a 30-day option to purchase additional shares of common stock. There can be no assurance as to whether or when the proposed offering may be completed, or as
About this update from Lexicon Pharmaceuticals, Inc.
[{"type":"image","alt":"Lexicon Pharmaceuticals, Inc.","displaySize":"","headline":null,"caption":"Lexicon Pharmaceuticals, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":166,"height":50,"url":"https://media.zenfs.com/en/globenewswire.com/4d6e4fe42ab02751f185e7d242d7f8e8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/bhkXAP8bO_Q1Z4PDGMz_0w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTYzO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/4d6e4fe42ab02751f185e7d242d7f8e8","width":166,"height":50}},"lazy":false},{"type":"text","content":"THE WOODLANDS, Texas, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced that it has commenced an underwritten public offering to offer and sell, subject to market and other conditions, shares of its common stock, par value $0.001. In addition, Lexicon intends to grant the underwriters a 30-day option to purchase additional shares of common stock. There can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the proposed offering.","length":553,"tagName":"p"},{"type":"text","content":"Jefferies and Piper Sandler are acting as joint book-running managers for the proposed offering.","length":96,"tagName":"p"},{"type":"text","content":"Concurrently with the closing of the underwritten public offering, Lexicon intends to sell shares of its common stock in a private placement to an affiliate of Invus, L.P., Lexicon’s largest stockholder, pursuant to its preemptive right under Lexicon’s Sixth Amended and Restated Certificate of Incorporation. Lexicon intends to grant the private placement purchaser an option to purchase, on a pro rata basis, additional shares of common stock to the extent the underwriters exercise their option to purchase additional common stock. Any shares of common stock offered pursuant to the concurrent private placement would not be registered under the Securities Act of 1933, as amended (the “Securities Act”). The closing of the underwritten public offering is not conditioned on the closing of the concurrent private placement.","length":826,"tagName":"p"},{"type":"text","content":"Lexicon currently intends to use the net proceeds that it will receive from the proposed offering (i) to fund the continued research and development of its drug candidates and (ii)...